Similar articles for PMID: 28708480

Year	Number of Results
1994	1
2009	2
2010	1
2011	1
2012	2
2014	1
2015	10
2016	10
2017	9
2018	19
2019	21
2020	19
2021	16
2022	14
2023	3
2024	0

1

Optimizing diabetes treatment in the presence of obesity.

Esquivel MA, Lansang MC. Esquivel MA, et al. Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S22-S29. doi: 10.3949/ccjm.84.s1.04. Cleve Clin J Med. 2017. PMID: 28708480 Free article. Review.

2

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.

Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Hu M, et al. J Am Heart Assoc. 2020 Apr 7;9(7):e015323. doi: 10.1161/JAHA.119.015323. Epub 2020 Mar 30. J Am Heart Assoc. 2020. PMID: 32223390 Free PMC article.

3

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.

Gurgle HE, White K, McAdam-Marx C. Gurgle HE, et al. Vasc Health Risk Manag. 2016 Jun 4;12:239-49. doi: 10.2147/VHRM.S83088. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27350752 Free PMC article. Review.

4

Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.

Patoulias D, Katsimardou A, Kalogirou MS, Zografou I, Toumpourleka M, Imprialos K, Stavropoulos K, Stergiou I, Papadopoulos C, Doumas M. Patoulias D, et al. Diabetes Metab. 2020 Sep;46(4):272-279. doi: 10.1016/j.diabet.2020.04.001. Epub 2020 May 8. Diabetes Metab. 2020. PMID: 32437914

5

Weight loss differences seen between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for treatment of type 2 diabetes.

Frieling K, Monte SV, Jacobs D, Albanese NP. Frieling K, et al. J Am Pharm Assoc (2003). 2021 Nov-Dec;61(6):772-777. doi: 10.1016/j.japh.2021.06.015. Epub 2021 Jun 17. J Am Pharm Assoc (2003). 2021. PMID: 34266747

6

How to fight obesity with antidiabetic drugs: targeting gut or kidney?

Baretić M, Troskot R. Baretić M, et al. Minerva Endocrinol. 2015 Mar;40(1):71-83. Epub 2014 Nov 4. Minerva Endocrinol. 2015. PMID: 25366984 Review.

7

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.

Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J. Wang Z, et al. Diabetes Obes Metab. 2018 Jan;20(1):113-120. doi: 10.1111/dom.13047. Epub 2017 Aug 10. Diabetes Obes Metab. 2018. PMID: 28656707 Review.

8

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, Tunnicliffe D, Ruospo M, Natale P, Saglimbene V, Nicolucci A, Johnson DW, Tonelli M, Rossi MC, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque LI, Lloyd A, Ahmad N, Liu Y, Tiv S, Millard T, Gagliardi L, Kolanu N, Barmanray RD, McMorrow R, Raygoza Cortez AK, White H, Chen X, Zhou X, Liu J, Rodríguez AF, González-Colmenero AD, Wang Y, Li L, Sutanto S, Solis RC, Díaz González-Colmenero F, Rodriguez-Gutierrez R, Walsh M, Guyatt G, Strippoli GFM. Palmer SC, et al. BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573. BMJ. 2021. PMID: 33441402 Free PMC article.

9

Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.

Lajara R. Lajara R. Postgrad Med. 2019 Nov;131(8):555-565. doi: 10.1080/00325481.2019.1670017. Epub 2019 Oct 3. Postgrad Med. 2019. PMID: 31580737 Review.

10

Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.

Carretero Gómez J, Arévalo Lorido JC, Gómez Huelgas R, García de Lucas D, Mateos Polo L, Varela Aguilar JM, Seguí Ripoll JM, Ena J; Diabetes, Obesity, and Nutrition Spanish Working Group. Carretero Gómez J, et al. Can J Diabetes. 2019 Apr;43(3):186-192. doi: 10.1016/j.jcjd.2018.09.001. Epub 2018 Sep 8. Can J Diabetes. 2019. PMID: 30415909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year